- Primary pulmonary epithelioid inflammatory myofibroblastic sarcoma: a rare entity and a literature review
-
Singh P, Nambirajan A, Gaur MK, Raj R, Kumar S, Malik PS, Jain D
- KMID: 2531616
- J Pathol Transl Med.
- 2022 Jul;56(4):231-237.
- doi: 10.4132/jptm.2022.05.08
Epithelioid inflammatory myofibroblastic sarcoma (EIMS) is an aggressive subtype of inflammatory myofibroblastic tumor (IMT) harboring anaplastic lymphoma kinase (ALK) gene fusions and is associated with high risk of local recurrence... -
- CITED
-
- Close
- SHARE
-
- Close
- Lorlatinib Therapy for Rapid and Dramatic Control of Brain and Spinal Leptomeningeal Metastases From ALK-Positive Lung Adenocarcinoma
-
Sun MG, Kim IY, Kim YJ, Jung TY, Moon KS, Jung S, Oh IJ, Kim YC, Choi YD
- KMID: 2522227
- Brain Tumor Res Treat.
- 2021 Oct;9(2):100-105.
- doi: 10.14791/btrt.2021.9.e19
We report a patient with severe neurological deterioration due to leptomeningeal metastases involving brain and spinal cord from anaplastic lymphoma kinase (ALK)-positive lung adenocarcinoma, managed rapidly and successfully with lorlatinib... -
- CITED
-
- Close
- SHARE
-
- Close
- Anaplastic Lymphoma Kinase Positive Large B-cell Lymphoma Mimicking Metastatic Carcinoma of the Cervical Lymph Node from an Unknown Primary Lesion
-
Kim SW, Lee K, Kim BH, Kim EJ
- KMID: 2521701
- Korean J Otorhinolaryngol-Head Neck Surg.
- 2021 Oct;64(10):760-765.
- doi: 10.3342/kjorl-hns.2020.00703
Anaplastic lymphoma kinase positive large B-cell lymphoma (ALK+LBCL) is a rare subtype of B-cell lymphoma with aggressive features and a poor prognosis. The rarity of this disease and similarity of... -
- CITED
-
- Close
- SHARE
-
- Close
- A case of concomitant EGFR/ALK alteration against a mutated EGFR background in early-stage lung adenocarcinoma
-
Lee KC, Koh J, Chung DH, Jeon YK
- KMID: 2513900
- J Pathol Transl Med.
- 2021 Mar;55(2):139-144.
- doi: 10.4132/jptm.2020.12.16
Rare cases of lung adenocarcinoma (LUAD) with concomitant epidermal growth factor receptor (EGFR) mutation and anaplastic lymphoma kinase (ALK) translocation have been reported. However, their clonal and evolutional relationship remains... -
- CITED
-
- Close
- SHARE
-
- Close
- Detection of Targetable Genetic Alterations in Korean Lung CancerPatients: A Comparison Study of Single-Gene Assays andTargeted Next-Generation Sequencing
-
Park E, Shim HS
- KMID: 2500339
- Cancer Res Treat.
- 2020 Apr;52(2):543-551.
- doi: 10.4143/crt.2019.305
Purpose Epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), and ROS proto-oncogene 1 (ROS1) are ‘must-test’ biomarkers in the molecular diagnostics of advanced- stage lung cancer patients. Although single-gene assays are currently... -
- CITED
-
- Close
- SHARE
-
- Close
- A Case of CD 30＋/ALK− Primary Systemic Anaplastic Large Cell Lymphoma Presenting a Sporotrichoid Pattern
-
Shin YB, Jo JW, Kim CY
- KMID: 2502807
- Korean J Dermatol.
- 2020 Mar;58(3):200-203.
Systemic anaplastic large cell lymphoma (ALCL) is an aggressive CD30-positive non-Hodgkin lymphoma. The most common clinical manifestations of systemic ALCL are solitary or multiple large nodular tumoral lesions confined to... -
- CITED
-
- Close
- SHARE
-
- Close
- Characteristics of Renal Cell Carcinoma Harboring TPM3-ALK Fusion
-
Woo CG, Yun SJ, Son SM, Lim YH, Lee OJ
- KMID: 2470924
- Yonsei Med J.
- 2020 Mar;61(3):262-266.
- doi: 10.3349/ymj.2020.61.3.262
The World Health Organization 2016 edition assigned anaplastic lymphoma kinase (ALK) rearrangement-associated renal cell carcinoma (ALK-RCC) as an emerging renal tumor entity. Identifying ALK-RCC is important because ALK inhibitors have... -
- CITED
-
- Close
- SHARE
-
- Close
- Clinical factors affecting progression-free survival with crizotinib in ALK-positive non-small cell lung cancer
-
Ock CY, Yoo SH, Keam B, Kim M, Kim TM, Jeon YK, Kim DW, Chung DH, Heo DS
- KMID: 2457035
- Korean J Intern Med.
- 2019 Sep;34(5):1116-1124.
- doi: 10.3904/kjim.2018.011
BACKGROUND/AIMS: Although crizotinib is standard chemotherapy for advanced anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC), clinical factors affecting progression-free survival (PFS) have not been reported. The purpose of... -
- CITED
-
- Close
- SHARE
-
- Close
- Alterations in PD-L1 Expression Associated with Acquisition of Resistance to ALK Inhibitors in ALK-Rearranged Lung Cancer
-
Kim SJ, Kim S, Kim DW, Kim M, Keam B, Kim TM, Lee Y, Koh J, Jeon YK, Heo DS
- KMID: 2454314
- Cancer Res Treat.
- 2019 Jul;51(3):1231-1240.
- doi: 10.4143/crt.2018.486
PURPOSE: The purpose of this study was to evaluate the relationships between the resistance of anaplastic lymphoma kinase (ALK)‒positive non-small cell lung cancer (NSCLC) to ALK inhibitors and the programmed... -
- CITED
-
- Close
- SHARE
-
- Close
- Crizotinib in Combination with Everolimus Synergistically Inhibits Proliferation of Anaplastic Lymphoma Kinase‒Positive Anaplastic Large Cell Lymphoma
-
Xu W, Kim JW, Jung WJ, Koh Y, Yoon SS
- KMID: 2411148
- Cancer Res Treat.
- 2018 Apr;50(2):599-613.
- doi: 10.4143/crt.2016.357
PURPOSE: Anaplastic large cell lymphoma (ALCL) is a rare aggresive non-Hodgkin lymphoma, of which over 50% of cases have an aberrant nucleophosmin (NPM)‒anaplastic lymphoma kinase (ALK) fusion protein. Both mechanistic... -
- CITED
-
- Close
- SHARE
-
- Close
- ALK Protein Expression Is Related to Neuroblastoma Aggressiveness But Is Not Independent Prognostic Factor
-
Lee JW, Park SH, Kang HJ, Park KD, Shin HY, Ahn HS
- KMID: 2411138
- Cancer Res Treat.
- 2018 Apr;50(2):495-505.
- doi: 10.4143/crt.2016.577
PURPOSE: In this study, anaplastic lymphoma kinase (ALK) mutation and amplification, ALK protein expression, loss of the nuclear alpha thalassemia/mental retardation syndrome X-linked (ATRX) protein, and telomerase reverse transcriptase (TERT)... -
- CITED
-
- Close
- SHARE
-
- Close
- Anaplastic lymphoma kinase (ALK)-expressing Lung Adenocarcinoma with Combined Neuroendocrine Component or Neuroendocrine Transformation: Implications for Neuroendocrine Transformation and Response to ALK-tyrosine Kinase Inhibitors
-
Sim J, Kim H, Hyeon J, Choi YL, Han J
- KMID: 2408058
- J Korean Med Sci.
- 2018 Apr;33(15):e123.
- doi: 10.3346/jkms.2018.33.e123
BACKGROUND: Anaplastic lymphoma kinase tyrosine kinase inhibitors (ALK-TKIs) are usually effective in lung adenocarcinoma patients with anaplastic lymphoma kinase (ALK) rearrangement. However, even after a good response to ALK-TKI therapy,... -
- CITED
-
- Close
- SHARE
-
- Close
- Efficacy of Pemetrexed-based Chemotherapy in Comparison to Non-Pemetrexed-based Chemotherapy in Advanced, ALK+ Non-Small Cell Lung Cancer
-
Jo J, Kim SH, Kim YJ, Lee J, Kim M, Keam B, Kim TM, Kim DW, Heo DS, Chung JH, Jeon YK, Lee JS
- KMID: 2418782
- Yonsei Med J.
- 2018 Mar;59(2):202-210.
- doi: 10.3349/ymj.2018.59.2.202
PURPOSE: Previous retrospective studies suggest that anaplastic lymphoma kinase (ALK) mutation-positive (ALK+) non-small cell lung cancer (NSCLC) patients are sensitive to pemetrexed. To determine its efficacy, we retrospectively evaluated clinical... -
- CITED
-
- Close
- SHARE
-
- Close
- Molecular Targeted Therapy in Modern Oncology: Imaging Assessment of Treatment Response and Toxicities
-
Krajewski , Braschi-Amirfarzan M, DiPiro PJ, Jagannathan JP, Shinagare
- KMID: 2468120
- Korean J Radiol.
- 2017 Feb;18(1):28-41.
- doi: 10.3348/kjr.2017.18.1.28
Oncology is a rapidly evolving field with a shift toward personalized cancer treatment. The use of therapies targeted to the molecular features of individual tumors and the tumor microenvironment has... -
- CITED
-
- Close
- SHARE
-
- Close
- CD30-Positive Anaplastic Lymphoma Kinase-Negative Systemic Anaplastic Large-Cell Lymphoma in a 9-Year-Old Boy
-
Kim JE, Oh EH, Ro YS, Ko JY
- KMID: 2164646
- Ann Dermatol.
- 2016 Jun;28(3):371-374.
- doi: 10.5021/ad.2016.28.3.371
Anaplastic large-cell lymphoma (ALCL) is a CD30-positive T-cell/null-cell lymphoma that is clinically classified into either primary cutaneous ALCL or systemic ALCL (S-ALCL) sub-types. Because 90% of childhood S-ALCL cases are... -
- CITED
-
- Close
- SHARE
-
- Close
- Non-small Cell Lung Cancer with Concomitant EGFR, KRAS, and ALK Mutation: Clinicopathologic Features of 12 Cases
-
Lee T, Lee B, Choi YL, Han J, Ahn MJ, Um SW
- KMID: 2164596
- J Pathol Transl Med.
- 2016 May;50(3):197-203.
- doi: 10.4132/jptm.2016.03.09
BACKGROUND: Although epidermal growth factor receptor (EGFR), v-Ki-ras2 Kirsten rat sarcoma viral oncogene (KRAS), and anaplastic lymphoma kinase (ALK) mutations in non-small cell lung cancer (NSCLC) were thought to be... -
- CITED
-
- Close
- SHARE
-
- Close
- SEC31A-ALK Fusion Gene in Lung Adenocarcinoma
-
Kim RN, Choi YL, Lee MS, Lira ME, Mao M, Mann D, Stahl J, Licon A, Choi SJ, Vrancken M, Han J, Wlodarska , Kim J
- KMID: 2152299
- Cancer Res Treat.
- 2016 Jan;48(1):398-402.
- doi: 10.4143/crt.2014.254
Anaplastic lymphoma kinase (ALK) fusion is a common mechanism underlying pathogenesis of non-small cell lung carcinoma (NSCLC) where these rearrangements represent important diagnostic and therapeutic targets. In this study, we... -
- CITED
-
- Close
- SHARE
-
- Close
- Uterine Cervix Metastasis in Lung Adenocarcinoma with Anaplastic Lymphoma Kinase Rearrangement
-
Choi S, Park CK, Kim SY, Yoon HK, Ro SM, Nam Y
- KMID: 2317776
- Soonchunhyang Med Sci.
- 2015 Dec;21(2):142-145.
- doi: 10.0000/sms.2015.21.2.142
The importance of anaplastic lymphoma kinase (ALK) as an oncogene in non-small cell lung cancer (NSCLC) has emerged as a major concern due to a dramatic clinical effect of targeted... -
- CITED
-
- Close
- SHARE
-
- Close
- Analysis of Histologic Features Suspecting Anaplastic Lymphoma Kinase (ALK)-Expressing Pulmonary Adenocarcinoma
-
Choi IH, Kim DW, Ha SY, Choi YL, Lee HJ, Han J
- KMID: 2151140
- J Pathol Transl Med.
- 2015 Jul;49(4):310-317.
- doi: 10.4132/jptm.2015.05.13
BACKGROUND: Since 2007 when anaplastic lymphoma kinase (ALK) rearrangements were discovered in non-small cell lung cancer, the ALK gene has received attention due to ALK-targeted therapy, and a notable treatment... -
- CITED
-
- Close
- SHARE
-
- Close
- The Impact of Molecularly Targeted Treatment on Direct Medical Costs in Patients with Advanced Non-small Cell Lung Cancer
-
Lee JK, Kim DW, Keam B, Kim TM, Lee SH, Kim YJ, Heo DS
- KMID: 2132796
- Cancer Res Treat.
- 2015 Apr;47(2):182-188.
- doi: 10.4143/crt.2013.227
PURPOSE: To investigate the impact of targeted treatment on direct medical costs of patients with advanced non-small cell lung cancer (NSCLC). MATERIALS AND METHODS: Medical records of 108 stage IIIB/IV NSCLC... -
- CITED
-
- Close
- SHARE
-
- Close
